{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:49:16Z","timestamp":1782197356945,"version":"3.54.5"},"reference-count":52,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Baseline lymphopenia is common among advanced solid tumors and may influence the efficacy\/safety of immune checkpoint inhibitors (ICIs), but large real-world evidence is limited. We evaluated the association between baseline absolute lymphocyte count (ALC) and clinical outcomes in adults with solid tumors treated with ICIs in routine practice. Methods: We performed a retrospective cohort study using TriNetX. Adults with solid tumors who received pembrolizumab, nivolumab, or atezolizumab (ICI-Na\u00efve) between January 2015 and June 2026 were included. Baseline ALC was measured within 30 days before first treatment and was classified as lymphopenic (ALC &lt; 1.5 \u00d7 109\/L) or non-lymphopenic (ALC \u2265 1.5 \u00d7 109\/L). Propensity score matching (1:1) yielded 5249 patients per group. The index date was the first immunotherapy date, and outcomes were assessed at 6, 12, 24, 36 months, and 5 years. The primary outcome was 24-month overall survival (OS); secondary outcomes were OS at 6 and 12 months and 6-month risks of healthcare utilization, immune-related adverse events (irAEs), and serious infections; and exploratory outcomes included OS at 36 months and 5 years. All outcomes were analyzed using Kaplan\u2013Meier analysis, Cox proportional hazards models, and risk ratios. Subgroup analysis included OS stratified by solid tumor subtypes and prior lines of therapy. Results: After matching, patients with baseline lymphopenia had consistently worse OS. Compared with patients without lymphopenia, the lymphopenia cohort had lower OS at 6 months (HR 1.29, 95% CI 1.22\u20131.37), 12 months (HR 1.28, 95% CI 1.21\u20131.35), 24 months (HR 1.26, 95% CI 1.2\u20131.33), and, in exploratory analyses with substantial right censoring and limited observed follow-up, 36 months (HR 1.26, 95% CI 1.2\u20131.33) and 5 years (HR 1.26, 95% CI 1.2\u20131.33), though these estimates should be considered hypothesis-generating only. At 6 months, baseline lymphopenia was associated with a greater healthcare utilization (RR 1.05, 95% CI 1.02\u20131.09), a higher infection risk (RR 1.08, 95% CI 1.01\u20131.15), and similar rates of clinically coded irAEs (RR 1.0, 95% CI 0.93\u20131.09), an observation subject to competing risk from early mortality in the lymphopenic cohort. Subgroup analysis, stratified by tumor subtypes and prior lines of therapy, showed consistently lower OS in the lymphopenia group, consistent with the primary outcome results. Conclusions: In this large propensity-matched real-world analysis of 10,498 patients with diverse solid tumors, baseline lymphopenia at ICI initiation was associated with persistently inferior OS at 6, 12, and 24 months (primary and secondary endpoints), greater early healthcare utilization, and a higher serious infection risk. Critically, lymphopenic patients developed irAEs at an identical rate to non-lymphopenic patients despite worse survival, a dissociation suggesting that baseline ALC stratifies patients along mortality risk and immune activation capacity as partially independent axes. These findings could support the use of baseline ALC as a simple, universally available biomarker that informs not only survival prognosis but also the anticipated toxicity profile of ICI therapy and highlight the need for competing-risk analyses and prospective immune phenotyping to characterize this relationship fully.<\/jats:p>","DOI":"10.3390\/cancers18121940","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:01:27Z","timestamp":1781492487000},"page":"1940","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline Lymphopenia Predicts Survival in ICI-Na\u00efve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1587-0370","authenticated-orcid":false,"given":"Ahmed","family":"Ismail","sequence":"first","affiliation":[{"name":"Department of Medicine, Eastern Virginia Medical School, Old Dominion University, Norfolk, VA 23507, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Balanchivadze","sequence":"additional","affiliation":[{"name":"Virginia Oncology Associates, Norfolk, VA 23502, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ohio Health, Columbus, OH 43228, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanis","family":"Boumber","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ohio Health, Delaware, OH 43015, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/OTT.S153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: A review and meta-analysis","volume":"11","author":"Sacdalan","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rugambwa, T.K., Abdihamid, O., Zhang, X., Peng, Y., Cai, C., Shen, H., Zeng, S., and Qiu, W. (2023). Neutrophil\u2013lymphocyte ratio and platelet\u2013lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1181248"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00030","article-title":"Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1\/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis","volume":"1","author":"Khunger","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fitzsimmons, T.S., Singh, N., Walker, T.D.J., Newton, C., Evans, D.G.R., Crosbie, E.J., and Ryan, N.A.J. (2023). Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: A systematic review and meta-analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1192762"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: From prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in Patients With Severe Lymphopenia Following Treatment with Radiation and Chemotherapy for Newly Diagnosed Solid Tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","first-page":"100852","article-title":"Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives","volume":"49","author":"Yaromina","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1916526","DOI":"10.1001\/jamanetworkopen.2019.16526","article-title":"Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population","volume":"2","author":"Zidar","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.5603\/CJ.a2020.0141","article-title":"Lymphopenia and mortality among patients undergoing coronary angiography: Long-term follow-up study","volume":"29","author":"Zafrir","year":"2022","journal-title":"Cardiol. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: An opportunity for combination with Cytokines?","volume":"7","author":"Blay","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","article-title":"Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas","volume":"69","author":"Cropet","year":"2009","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, X., Meng, F., and Jiang, R. (2021). Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.746976"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1002\/cam4.6645","article-title":"Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy","volume":"12","author":"Goldschmidt","year":"2023","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44276-024-00058-6","article-title":"Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors","volume":"2","author":"Conroy","year":"2024","journal-title":"BJC Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Young, R.B., Panchal, H., Ma, W., Chen, S., Steele, A., Iannucci, A., and Li, T. (2022). Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.980181"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Egami, S., Kawazoe, H., Hashimoto, H., Uozumi, R., Arami, T., Sakiyama, N., Ohe, Y., Nakada, H., Aomori, T., and Ikemura, S. (2021). Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients with Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.618570"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108555","DOI":"10.1016\/j.lungcan.2025.108555","article-title":"Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens","volume":"204","author":"Sugai","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101038","DOI":"10.1016\/j.adro.2022.101038","article-title":"Meta-Analysis and Critical Review: Association Between Radio-Induced Lymphopenia and Overall Survival in Solid Cancers","volume":"8","author":"Massard","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102119","DOI":"10.1016\/j.suronc.2024.102119","article-title":"The effect of long-standing lymphopenia after radiation therapy on survival in rectal cancer","volume":"56","author":"Soyfer","year":"2024","journal-title":"Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1093\/oncolo\/oyad094","article-title":"Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy","volume":"28","author":"Cheng","year":"2023","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4143\/crt.2024.493","article-title":"Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non-Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor","volume":"57","author":"Lee","year":"2025","journal-title":"Cancer Res. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tomsitz, D., Schlaak, M., Zierold, S., Pesch, G., Schulz, T.U., M\u00fcller, G., Zecha, C., French, L.E., and Heinzerling, L. (2022). Development of Lymphopenia During Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14133282"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Byun, H.K., Chang, J.S., Jung, M., Koom, W.S., Chung, K.Y., Oh, B.H., Roh, M.R., Kim, K.H., Lee, C.-K., and Shin, S.J. (2021). Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients with Melanoma Based on Easily Accessible Clinical Indicators. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.659754"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Navarro-Mart\u00ednez, R., and Cauli, O. (2021). Lymphocytes as a Biomarker of Frailty Syndrome: A Scoping Review. Diseases, 9.","DOI":"10.3390\/diseases9030053"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2017.07.033","article-title":"Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1\/PD-L1 inhibitors)","volume":"84","author":"Sun","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Teijeira, L., Mart\u00ednez, M., Moreno, A., de Elejoste, I., Ib\u00e1\u00f1ez-Beroiz, B., Arrazubi, V., D\u00edaz de Corcuera, I., Elejalde, I., Campillo-Calatayud, A., and Les, I. (2023). Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender Perspective. Cancers, 16.","DOI":"10.3390\/cancers16010151"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, B., Li, D., Yang, Y., Lin, S., Zhao, R., Li, Y., and Peng, L. (2025). Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1528084"},{"key":"ref_34","first-page":"29","article-title":"A baseline-lymphocyte-subset nomogram for predicting severe immune-related adverse events in hepatocellular carcinoma patients receiving TACE plus immunotherapy","volume":"11","author":"Yu","year":"2025","journal-title":"Hepatoma Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaad.2022.12.049","article-title":"Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy","volume":"88","author":"Asdourian","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Warny, M., Helby, J., Nordestgaard, B.G., Birgens, H., and Bojesen, S.E. (2018). Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002685"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12935-020-1094-5","article-title":"Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: A systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non\u2013Small Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kang, Y.-W., Choi, D., Moon, D., Lee, K.-J., Oh, Y., Yang, J., Jeong, S., Park, U., Im, S.-K., and Yang, S.H. (2024). Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1477171"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41598-021-04630-9","article-title":"Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41416-025-03069-3","article-title":"GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+\/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours","volume":"133","author":"Kim","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e98960","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: The IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/annonc\/mdv173","article-title":"ELYPSE-7: A randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients","volume":"26","author":"Garin","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1002\/cam4.5467","article-title":"Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma","volume":"12","author":"Ahn","year":"2023","journal-title":"Cancer Med."},{"key":"ref_46","unstructured":"(2026, June 07). An Open-label Phase 1b\/2a Study of NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Subjects with Relapsed\/Refractory Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04332653."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40425-019-0551-y","article-title":"Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy","volume":"7","author":"Knudson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lui, G., Minnar, C.M., Soon-Shiong, P., Schlom, J., and Gameiro, S.R. (2023). Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies. Cells, 12.","DOI":"10.3390\/cells12121611"},{"key":"ref_49","unstructured":"(2026, June 07). Phase I Study of Recombinant Interleukin 15 in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03388632."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100046","DOI":"10.1016\/j.esmoop.2020.100046","article-title":"Immune cell engagers in solid tumors: Promises and challenges of the next generation immunotherapy","volume":"6","author":"Spagnoletti","year":"2021","journal-title":"ESMO Open"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"ltae005","DOI":"10.1093\/immadv\/ltae005","article-title":"Bispecific T-cell engagers for the recruitment of T cells in solid tumors: A literature review","volume":"5","author":"Dewaele","year":"2025","journal-title":"Immunother. Adv."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Spinazzola, A., Iannantuono, G.M., Gulley, J.L., Giudice, E., Filetti, M., Sganga, S., Bianco, F.L., Floudas, C.S., and Daniele, G. (2025). Current landscape of T-cell engagers in early-phase clinical development in solid cancers. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1665838"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1940\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:35:02Z","timestamp":1782196502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121940"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121940","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]}}}